Dr. Stephanie Magdanz is a pharmacist who is specialized in Oncology in Boise, Idaho. Patients can reach her at 500 W Fort St, Boise or contact her on 208-422-1000. Active license number of Dr. Stephanie Magdanz is P5389 for Oncology in Idaho. Dr. Stephanie Magdanz is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Dr. Stephanie Magdanz speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Stephanie Magdanz
Specialization:
Oncology
Credentials:
PHARM.D., BCOP
Gender:
Female
Location:
500 W Fort St, Boise, Idaho, 83702-4501
Phone:
208-422-1000
Fax:
208-422-1269
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Stephanie Magdanz are as mentioned below.
NPI Number:
1952791071
NPI Enumeration Date:
27 Jan, 2015
NPI Last Update On:
27 Jan, 2015
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Stephanie Magdanz are as mentioned below.
Specialization
License Number
State
Status
Oncology
P5389
Idaho
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
500 W Fort St, Boise, Idaho
Zip:
83702-4501
Phone Number:
208-422-1000
Fax Number:
208-422-1269
Patients can reach Dr. Stephanie Magdanz at 500 W Fort St, Boise, Idaho or can call on phone at 208-422-1000.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.